About
Technology
Issues
FAQ
Links
Official Page
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.